Kamada Ltd. (KMDA)
USD 6.09
(3.05%)
USD 6.09
(3.05%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 45.42 Million USD | -1.74% |
| 2022 | 42.17 Million USD | 35.93% |
| 2021 | 31.02 Million USD | 9.57% |
| 2020 | 28.31 Million USD | 5.05% |
| 2019 | 26.95 Million USD | 21.34% |
| 2018 | 22.21 Million USD | -9.86% |
| 2017 | 24.64 Million USD | -9.17% |
| 2016 | 27.13 Million USD | -1.09% |
| 2015 | 27.42 Million USD | 3.42% |
| 2014 | 26.52 Million USD | 16.8% |
| 2013 | 22.7 Million USD | 23.04% |
| 2012 | 18.45 Million USD | 2.31% |
| 2011 | 18.03 Million USD | 7.33% |
| 2010 | 16.8 Million USD | 13.4% |
| 2009 | 14.82 Million USD | -13.4% |
| 2008 | 17.11 Million USD | -4.56% |
| 2007 | 17.92 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 13.12 Million USD | 5.66% |
| 2024 Q1 | 12.59 Million USD | 2.85% |
| 2023 Q4 | 12.24 Million USD | 17.39% |
| 2023 FY | 41.43 Million USD | -1.74% |
| 2023 Q2 | 11.8 Million USD | 2.21% |
| 2023 Q3 | 10.43 Million USD | -11.61% |
| 2023 Q1 | 11.55 Million USD | 2.46% |
| 2022 Q4 | 11.27 Million USD | 9.36% |
| 2022 Q3 | 10.3 Million USD | 8.12% |
| 2022 FY | 42.17 Million USD | 35.93% |
| 2022 Q1 | 11.05 Million USD | 11.71% |
| 2022 Q2 | 9.53 Million USD | -13.77% |
| 2021 Q4 | 9.89 Million USD | 51.47% |
| 2021 Q2 | 8.02 Million USD | 22.22% |
| 2021 Q3 | 6.53 Million USD | -18.59% |
| 2021 FY | 31.02 Million USD | 9.57% |
| 2021 Q1 | 6.56 Million USD | -12.63% |
| 2020 Q4 | 7.51 Million USD | 6.49% |
| 2020 Q2 | 7.14 Million USD | 8.17% |
| 2020 Q1 | 6.6 Million USD | -0.05% |
| 2020 Q3 | 7.05 Million USD | -1.15% |
| 2020 FY | 28.31 Million USD | 5.05% |
| 2019 FY | 26.95 Million USD | 21.34% |
| 2019 Q3 | 7.16 Million USD | -0.56% |
| 2019 Q4 | 6.6 Million USD | -7.86% |
| 2019 Q2 | 7.2 Million USD | 20.62% |
| 2019 Q1 | 5.97 Million USD | 1.75% |
| 2018 Q1 | 5.78 Million USD | 11.63% |
| 2018 Q4 | 5.87 Million USD | 16.44% |
| 2018 Q3 | 5.04 Million USD | -8.29% |
| 2018 FY | 22.21 Million USD | -9.86% |
| 2018 Q2 | 5.49 Million USD | -4.99% |
| 2017 Q3 | 6.76 Million USD | 1.11% |
| 2017 FY | 24.64 Million USD | -9.17% |
| 2017 Q4 | 5.18 Million USD | -23.32% |
| 2017 Q2 | 6.68 Million USD | 11.3% |
| 2017 Q1 | 6 Million USD | -12.43% |
| 2016 FY | 27.13 Million USD | -1.09% |
| 2016 Q1 | 6.75 Million USD | -9.6% |
| 2016 Q2 | 6.21 Million USD | -7.93% |
| 2016 Q3 | 7.29 Million USD | 17.3% |
| 2016 Q4 | 6.86 Million USD | -5.94% |
| 2015 Q2 | 6.09 Million USD | -0.75% |
| 2015 Q4 | 7.47 Million USD | -3.2% |
| 2015 Q3 | 7.71 Million USD | 26.62% |
| 2015 Q1 | 6.14 Million USD | 4.88% |
| 2015 FY | 27.42 Million USD | 3.42% |
| 2014 Q3 | 6.87 Million USD | -12.17% |
| 2014 Q1 | 5.96 Million USD | -7.71% |
| 2014 FY | 26.52 Million USD | 16.8% |
| 2014 Q2 | 7.82 Million USD | 31.08% |
| 2014 Q4 | 5.85 Million USD | -14.78% |
| 2013 Q3 | 4.96 Million USD | -13.96% |
| 2013 Q2 | 5.77 Million USD | 4.98% |
| 2013 FY | 22.7 Million USD | 23.04% |
| 2013 Q4 | 6.46 Million USD | 30.22% |
| 2013 Q1 | 5.49 Million USD | 22.01% |
| 2012 Q4 | 4.5 Million USD | 3.87% |
| 2012 FY | 18.45 Million USD | 2.31% |
| 2012 Q2 | 4.32 Million USD | 0.0% |
| 2012 Q3 | 4.33 Million USD | 0.37% |
| 2011 FY | 18.03 Million USD | 7.33% |
| 2010 FY | 16.8 Million USD | 13.4% |
| 2009 FY | 14.82 Million USD | -13.4% |
| 2008 FY | 17.11 Million USD | -4.56% |
| 2007 FY | 17.92 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -450.427% |
| Alpha Teknova, Inc. | 45.85 Million USD | 0.944% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 76.821% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -1.275% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 71.468% |
| Cosmos Health Inc. | 26.18 Million USD | -73.509% |
| Journey Medical Corporation | 54.59 Million USD | 16.793% |
| Embecta Corp. | 528.4 Million USD | 91.403% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 83.293% |
| Dynavax Technologies Corporation | 219.14 Million USD | 79.271% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 92.301% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 86.082% |
| PainReform Ltd. | 9.58 Million USD | -373.977% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -246.117% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -246.117% |
| SCYNEXIS, Inc. | 51.84 Million USD | 12.386% |
| Safety Shot Inc | 12.1 Million USD | -275.121% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -1380.066% |
| Procaps Group, S.A. | 199.47 Million USD | 77.227% |
| Theratechnologies Inc. | 72.75 Million USD | 37.564% |
| Harrow Health, Inc. | 89.97 Million USD | 49.512% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -380.902% |
| Biofrontera Inc. | 39.95 Million USD | -13.682% |
| DURECT Corporation | 43.71 Million USD | -3.914% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 91.413% |
| Cronos Group Inc. | 96.7 Million USD | 53.028% |
| OptiNose, Inc. | 85.1 Million USD | 46.622% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 80.43% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -16.022% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 575.118% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 85.539% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -366.825% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -5.542% |
| Radius Health, Inc. | 265.92 Million USD | 82.918% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -228.177% |
| ProPhase Labs, Inc. | 37.85 Million USD | -20.01% |
| Phibro Animal Health Corporation | 260.29 Million USD | 82.548% |
| Procaps Group S.A. | 187.24 Million USD | 75.74% |
| Alvotech | 285.43 Million USD | 84.086% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -362.351% |
| Viatris Inc. | 5.96 Billion USD | 99.239% |
| Rockwell Medical, Inc. | 15.37 Million USD | -195.473% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 24.088% |
| SIGA Technologies, Inc. | 22.04 Million USD | -106.079% |
| Tilray Brands, Inc. | 251.35 Million USD | 81.928% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 7.366% |
| Shineco, Inc. | 17.94 Million USD | -153.097% |
| PetIQ, Inc. | 192.72 Million USD | 76.43% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -1038.172% |
| Incannex Healthcare Limited | 30.05 Million USD | -51.153% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 97.155% |
| Alimera Sciences, Inc. | 62.64 Million USD | 27.482% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -5857.571% |
| Assertio Holdings, Inc. | 368.58 Million USD | 87.676% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -671.82% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -155.08% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -114.587% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -115.882% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 72.463% |
| Hempacco Co., Inc. | 7.59 Million USD | -497.99% |
| Talphera, Inc. | 11.99 Million USD | -278.739% |
| Alvotech | 285.43 Million USD | 84.086% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 67.717% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 86.829% |
| Currenc Group, Inc. | 24 Million USD | -89.259% |
| Indivior PLC | 911 Million USD | 95.014% |
| Evoke Pharma, Inc. | 12.4 Million USD | -266.054% |
| Flora Growth Corp. | 10.57 Million USD | -329.398% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -115.882% |
| Evolus, Inc. | 189.75 Million USD | 76.061% |
| HUTCHMED (China) Limited | 436.23 Million USD | 89.587% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 70.528% |
| Akanda Corp. | 3.48 Million USD | -1204.03% |